Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 1996

View Archived Issues

RPR continues research into taxanes

Antitumor enhancers claimed by Taiho

Japanese researchers disclose substance P antagonists

Phase IIa trial on Isis antiinflammatory antisense compound completed

Patent issued for Vical's core technology

New company formed with focus on women's health

E-Z-EM introduces new dysphagia diagnostic kit

Incyte and Abbott expand genomic database agreement

Priority review for Crinone

Sterinetics System successfully inactivates multiple viruses in IVIg

RTP to accelerate development of insoluble drug delivery technology

Houghten's lead CRA safe in diabetics

New patient-activated drug delivery system from Medtronic released in Europe

Moisture-managing foam wound dressing introduced

GenPharm generates human anti-IL-8 antibodies

Phase II trials begin on low-dose interferon alfa for Sjogren's syndrome

Shareholder meeting set to approve Bio-Dental-Zila merger

Cytel announces plans for Cylexin at investors conference

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...